Adding up the evidence
The Fall conference season continues apace!
As the Fall conference season continues its rounds through various cancer meetings, it’s time to take stock for a moment and look at what an in vivo CAR-T cell therapy, a TCR therapy, and a dual checkpoint combination all have in common.
The answer may well surprise a few people.
In our latest analysis and discussion we highlight some early approaches, which could have an impact in phase 2 development given the encouraging data reported so far. There’s also an intriguing biomarker that’s been identified, which could impact other IO combinations.
We’ve always argued in favour of waiting for more robust data at the recommended phase 2 dose (RP2D) because it’s much easier to judge activity and durability when you have an active dose, as opposed to many people receiving the early, suboptimal ones.
That said, there’s still quite a lot we can learn from the initial phase 1 evaluation in advanced solid tumours, particularly when the focus is deliberately narrowed to more rational and selective situations rather than random allcomers, as this report highlights…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
